Advertisement
Advertisement

COCP

COCP logo

Cocrystal Pharma, Inc. Common Stock

1.44
USD
Sponsored
+0.05
+3.60%
May 08, 16:00 UTC -4
Closed
exchange

After-Market

1.39

-0.05
-3.47%

Cocrystal Pharma, Inc. Common Stock Profile

About

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. CC-31244 is a Phase 2a ready broad-spectrum novel non-nucleoside replication inhibitor of HepC. Phase 1b studies in HepC infected patients showed the largest reduction in viral load of any non-nucleoside inhibitor tested to date. The next step for CC-31244 is clinical trials as part of a cocktail for ultra-short therapy of 2 to 6 weeks. The lead candidate for influenza has advanced to IND-enabling studies. It is effective in animal models against both the pandemic and seasonal strains of influenza. In addition, the Company has a pipeline of promising early preclinical programs. Two private investors own approximately 48% of the Company.

Info & Links

CEO

Sam Lee

Headquarters

19805 N. CREEK PARKWAY
BOTHELL, WA 98011, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.cocrystalpharma.com

Auditor

Weinberg & Company, P.A

Share holders

205

Employees

10

Cocrystal Pharma, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

19.16M

Enterprise Value

12.06M

Enterprise Value/EBITDA(ttm)

-1.40

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

3.11

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-132.61%

Return on Invested Capital(ttm)

-131.05%

Return on Assets(ttm)

-89.83%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-8.64M

Net Income Available to Common(ttm)

-8.83M

Diluted EPS(ttm)

-0.79

Share Statistics

Beta (5Y Monthly)

1.18

52-Week Change

-8.17%

S&P 500 52-Week Change

26.60%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

13.79M

Dividend Yield

0.00%

Float4

9.91M

% Held by Insiders

28.14%

% Held by Institutions

6.72%

Balance Sheet

Total Cash(mrq)

7.10M

Total Cash Per Share(mrq)

0.52

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

5.78%

Quick Ratio(mrq)

3.68%

Book Value Per Share(mrq)

0.59

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.59

Free Cash Flow(ytd)

-6.47M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement